Testosterone - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:12Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 12:		Line 12:
	\| halflife = Highly variable by formulation; native T is hours		\| halflife = Highly variable by formulation; native T is hours
	\| bioavailability = Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass)		\| bioavailability = Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass)
	\| pregnancy = Category X — contraindicated; teratogenic (virilization of female fetus)		\| pregnancy = Category X, contraindicated; teratogenic (virilization of female fetus)
	\| legal = Schedule III (DEA, US)		\| legal = Schedule III (DEA, US)
	\| mechanism = Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT.		\| mechanism = Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT.
Line 27:		Line 27:
	\| pregnancy_details = Category X. Women of reproductive potential exposed via transdermal partner contact must wash immediately.		\| pregnancy_details = Category X. Women of reproductive potential exposed via transdermal partner contact must wash immediately.
	\| monitoring = Total/free T (timed); H/H (polycythemia); PSA; lipids; LFTs (oral); sleep apnea screen.		\| monitoring = Total/free T (timed); H/H (polycythemia); PSA; lipids; LFTs (oral); sleep apnea screen.
	\| counseling = Avoid skin-to-skin contact with women/children for several hours after gel application. Erythrocytosis is common — monitor hematocrit. Suppresses endogenous production and impairs fertility — discuss sperm banking in patients who may want children.		\| counseling = Avoid skin-to-skin contact with women/children for several hours after gel application. Erythrocytosis is common, monitor hematocrit. Suppresses endogenous production and impairs fertility, discuss sperm banking in patients who may want children.
	\| anecdotes =		\| anecdotes =
	\| seealso = [[Flibanserin]]		\| seealso = [[Flibanserin]]

MDElliottMD: Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

2026-05-19T01:37:44Z

Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

← Older revision		Revision as of 01:37, 19 May 2026
Line 15:		Line 15:
	\| legal = Schedule III (DEA, US)		\| legal = Schedule III (DEA, US)
	\| mechanism = Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT.		\| mechanism = Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT.
	\| intro = Testosterone is the principal endogenous androgen and the most prescribed hormone therapy in adult men. Delivered through an unusually wide range of formulations because endogenous half-life is short and oral bioavailability of native testosterone is essentially zero. Off-label use for "low T" symptoms in men with normal levels remains controversial; clear ~~indications~~ are biochemical hypogonadism and gender-affirming care.		\| intro = Testosterone is the principal endogenous androgen and the most prescribed hormone therapy in adult men. Delivered through an unusually wide range of formulations because endogenous half-life is short and oral bioavailability of native testosterone is essentially zero. Off-label use for "low T" symptoms in men with normal levels remains controversial; clear problems are biochemical hypogonadism and gender-affirming care.
	\| indications =		\| indications =
	\| dosing =		\| dosing =

MDElliottMD: Create Testosterone scaffold

2026-05-15T15:30:24Z

Create Testosterone scaffold

New page

{{MedTemplate
| generic = Testosterone
| brand = AndroGel, Testim, Axiron, Fortesta (gels); Androderm (patch); Aveed (IM); Striant (buccal); Natesto (nasal); Jatenzo, Tlando (oral undecanoate)
| classes = Androgen / Anabolic Steroid
| uses = <vote slug="hypogonadism-use">Male hypogonadism</vote>, <vote slug="gender-affirming-hrt-use">Gender-affirming HRT</vote>, <vote slug="female-hsdd-use">HSDD in postmenopausal women (off-label)</vote>
| starting_dose = Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d.
| preparations = Gels, patches, IM cypionate/enanthate/undecanoate, buccal tabs, nasal gel, oral undecanoate, subcutaneous pellets
| fda_max = Formulation-dependent
| routes = Topical (gel/patch), IM, buccal, nasal, oral (undecanoate only)
| onset = Hours (transdermal); days (IM esters)
| duration = Hours (nasal); ~24 h (gel/patch); 1–2 weeks (cypionate/enanthate IM); ~10 weeks (undecanoate IM)
| halflife = Highly variable by formulation; native T is hours
| bioavailability = Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass)
| pregnancy = Category X — contraindicated; teratogenic (virilization of female fetus)
| legal = Schedule III (DEA, US)
| mechanism = Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT.
| intro = Testosterone is the principal endogenous androgen and the most prescribed hormone therapy in adult men. Delivered through an unusually wide range of formulations because endogenous half-life is short and oral bioavailability of native testosterone is essentially zero. Off-label use for "low T" symptoms in men with normal levels remains controversial; clear indications are biochemical hypogonadism and gender-affirming care.
| indications =
| dosing =
| effects =
| pk_absorption = Bypasses first-pass via non-oral routes; oral undecanoate uses lymphatic absorption.
| pk_distribution = ~98% bound (mostly SHBG, some albumin).
| pk_metabolism = Hepatic to inactive metabolites; aromatized to estradiol; reduced to DHT.
| pk_elimination = Renal as glucuronide and sulfate conjugates.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details = Category X. Women of reproductive potential exposed via transdermal partner contact must wash immediately.
| monitoring = Total/free T (timed); H/H (polycythemia); PSA; lipids; LFTs (oral); sleep apnea screen.
| counseling = Avoid skin-to-skin contact with women/children for several hours after gel application. Erythrocytosis is common — monitor hematocrit. Suppresses endogenous production and impairs fertility — discuss sperm banking in patients who may want children.
| anecdotes =
| seealso = [[Flibanserin]]
| references = <references/>
}}

[[Category:Medicines]]